Table 2.

Summary of some of the Raman techniques used for monitoring the effects of anticancer drugs on cancer tissues.

Monitoring Approach	Nanoparticles	Anticancer Drug	Raman Instrumentation	Target	Reference
Cancer response to anticancer drugs	Targeted Cet-PLGA- b-PEG and Non-targeted PLGA- b-PEG	Microtubule targeted vascular disrupting agents (MTVDA)	Confocal Spontaneous Raman Microscopy (λ = 532 nm; laser power on sample = 10 mW; integration time = 5 s; number of spectra acquired for each sample = 10)	Ex-vivo hepatocellular carcinomas	[50]
Monitoring of concentration of anticancer drug in cancer cell nucleus/ cytoplasm	Squalene	Doxorubicin	Confocal Spontaneous Raman Microscopy (λ = 785 nm; laser power on sample = 60 mW; integration time = 20 s; number of spectra acquired for each sample = 30)	Murine lung carcinomas and Human breast cancer	[51]
Assessing profiles of the release of anticancer drugs	Diatomic NP decorated with Au NPs and enclosed in gelatin shell	Galunisertib	SERS (λ = 638 nm; He-Ne laser power = 50 mW; laser power on sample = 1 mW; acquisition time = 1 s; SERS spectra collected from 30 cells) Raman imaging (λ = 638 nm; He-Ne laser power = 50 mW; laser power on sample = 20 mW; Raman images acquired by raster scanning with step size of 0.5 μm; number of spectra acquired per cell = 1500/2000)	Colorectal cancer	[52]